Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing

• First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof.
• Patient care and research delivered in collaboration with the Melbourne Theranostic Innovation Centre (MTIC), led by its world-class clinical research team.

MELBOURNE, Australia, July 16, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today officially opens a multi-million dollar radiopharmaceutical research, manufacturing and treatment facility in Melbourne, expanding and strengthening Australia’s capability in one of the world’s fastest-growing areas of cancer diagnosis and treatment.

Telix Manufacturing Solutions North Melbourne (TMSNM) is a purpose-built site that combines radiochemistry laboratories, clinical product manufacturing, patient dose administration and imaging. It is a first-of-its-kind Australian facility that integrates these capabilities at a single location. The facility will help address manufacturing capacity constraints and the need to make and administer radiopharmaceutical doses in close proximity to patients. It will link research, clinical trials and treatment, and is intended to significantly reduce the timeframe from early-stage trials to broad patient access.

Patient care and research at the site will be delivered by the Melbourne Theranostic Innovation Centre (MTIC), overseen by world-leading nuclear medicine clinician-researcher Professor Rod Hicks. The Telix and MTIC clinical research collaboration covers Telix-sponsored studies, investigator-initiated trials and select third party collaborations.

Dr. Christian Behrenbruch, Telix Managing Director and Group CEO, commented, “Radiopharmaceuticals are fast becoming an important part of cancer care, but manufacturing capacity for novel treatments, which needs to be near patients, remains a constraint in Australia. This facility will allow us to move new treatments from research into the clinic and patient use more efficiently. It is also an investment in Australia’s sovereign manufacturing capability and the specialist workforce needed to build a globally competitive radiopharmaceutical industry.”

Professor Rod Hicks, MTIC Founder, Chair and Chief Medical Officer, added, “Bringing these capabilities together will give clinicians faster access to novel radiopharmaceuticals and allow emerging technologies to be assessed in a real-world clinical setting. It will help us select patients more precisely, measure treatment response and generate evidence more quickly as we evaluate new targets and next generation isotopes and treatment approaches.”

Radiopharmaceuticals that can reveal the location of tumors on scans and deliver therapeutic radiation directly to cancer cells are rapidly emerging as the ‘sixth pillar’ of cancer care, alongside surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy.

TMSNM will also support training in nuclear medicine, radiochemistry, engineering and clinical research, helping develop the specialist workforce required by Australia’s health and life sciences sector.

About the Melbourne Theranostic Innovation Centre

The Melbourne Theranostic Innovation Centre (MTIC) is a clinical theranostics center led by Professor Rod Hicks. MTIC provides clinical imaging and administration of radionuclide therapy.  As a core mission, MTIC supports the development of new approaches to precision cancer diagnosis and treatment through ethics-approved clinical studies.

About Telix Manufacturing Solutions (TMS)

TMS is a global network of 45 manufacturing and distribution facilities across five continents, equipping Telix to deliver commercial and clinical doses to patients globally. Capabilities span isotope production, translational research and radiochemistry, antibody engineering, bioconjugation, and finished radiopharmaceutical manufacturing and distribution. Our TMS Brussels South site with nine GMP manufacturing lines, a radiopharmacy, and two cyclotrons across a 30,000 sq ft site is one of Europe’s largest radiopharmaceutical production facilities. In the United States, through our RLS network we are delivering more than 2.5 million patient doses annually. TMS Yokohama is Telix’s first cyclotron facility in the Asia Pacific region and TMS North Melbourne is a first-of-its kind facility in Australia integrating radiochemistry laboratories, clinical product manufacturing, patient dosing and imaging under one roof. Telix’s ARTMS QUANTM® Irradiation System (QIS®) advanced isotope production technology is being deployed at Telix cyclotron facilities worldwide, including select RLS radiopharmacies and TMS Brussels South and Yokohama.

About Telix Pharmaceuticals Limited

Telix (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. 

Telix’s commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), Telix’s next-generation PSMA-PET imaging agent approved by the U.S. FDA. The Company’s late-stage therapeutic pipeline includes three assets in pivotal-stage trials – TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (¹³¹I-iodofalan) in recurrent glioblastoma, TLX250-Tx (¹⁷⁷Lu-girentuximab) in kidney cancer, complemented by a deep pipeline of next generation assets. TLX591-Tx, TLX101-Tx and TLX250-Tx have not received marketing authorizations in any jurisdiction.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 
 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.